Monographie - Ceftolozane / tazobactam - Stabilis 4.0

Siste oppdatering :
08/05/2024

Antibiotika

Ceftolozane / tazobactam

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

Pdf

Kjemisk struktur

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Zepilen	Spania
Zerbaxa	Argentina, Chile, Ecuador, Frankrike, Mexico, Peru, Romania, Spania, Storbritannia, Sveits, Tyskland, USA

Referanser

Injeksjon

Referanser : Ceftolozane / tazobactam

	Type	Publikasjon
3520	Labratorium	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Labratorium	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Labratorium	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Labratorium	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3803	Labratorium	Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics Laboratoires Merck Sharp & Dohme Chibret 2020
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3984	Journal	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378	Journal	Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020 ; 40, 5: 470-476.
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Journal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4645	Journal	Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist 2021
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales